fbpx

molecules of the month

BMS-986318

oral FXR agonist for NASH

robust in vivo PD, phase I HV study withdrawn

from prior FXR agonists

ACS Med. Chem. Lett

Bristol Myers Squibb, Princeton, NJ, USA

BMS-986318
1 min read

The BMS spirocyclobutene-containing FXR agonist, BMS-986318, appears to have been intended as a clinical candidate, but was withdrawn from a planned Ph. I study. The molecule exhibits potent in vitro and in vivo activation of FXR (FXR Gal4 reporter EC50 = 53 nM, SRC-1 recruitment assay EC50 = 350 nM) and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis. This novel molecule displayed robust target engagement in vivo and is a rare example of a cyclobutene-containing, rationally designed drug-like molecule.


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: